Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.21%||69.57||1.0%||$514.09m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.19%||207.00||1.9%||$454.95m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.10%||654.70||2.7%||$419.81m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.00%||4.36||0.7%||$304.78m|
|EXAS||EXACT Sciences Corp.||0.84%||86.98||18.0%||$152.21m|
|TXG||10X Genomics, Inc.||1.89%||154.99||0.0%||$140.09m|
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.